Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0249


Improving survival with trastuzumab emtansine for HER2-positive breast cancer.

Charalabos Batsis, MD.

Affiliation: Charalabos Batsis, Associate Professor of Surgery, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.


Targeted therapy for HER2-posutive breast cancer subtype has dramatically evolved over the last few years. Trastuzumab added to chemotherapy improves survival and it has been the standard approach for advanced or metastatic disease with HER2 amplification but resistance and disease progression occurs with both this regimen [ 1,2] as well as with lapatinib plus capecitabine [3]. Here it is discussed the safety and efficacy of the EMILIA study, a randomized, phase 3 trial comparing trastuzumab emtansine (T-DM1) with lapatinib plus capecitabine for HER2-positive advanced breast cancer [4]. In addition, with the advent of clinical breast cancer genome landscape by applying next-generation sequencing technologies in breast cancer samples [5-10], the future perspectives and challenges are summarized towards further improvement in survival of patients with breast cancer.

(Citation: Gastric & Breast Cancer 2012; 11(4): 203-207)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 October 2012